<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35464467</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>26</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pathogenesis of Autoimmune Cytopenias in Inborn Errors of Immunity Revealing Novel Therapeutic Targets.</ArticleTitle>
        <Pagination>
          <StartPage>846660</StartPage>
          <MedlinePgn>846660</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">846660</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.846660</ELocationID>
        <Abstract>
          <AbstractText>Autoimmune diseases are usually associated with environmental triggers and genetic predisposition. However, a few number of autoimmune diseases has a monogenic cause, mostly in children. These diseases may be the expression, isolated or associated with other symptoms, of an underlying inborn error of immunity (IEI). Autoimmune cytopenias (AICs), including immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), autoimmune neutropenia (AN), and Evans' syndrome (ES) are common presentations of immunological diseases in the pediatric age, with at least 65% of cases of ES genetically determined. Autoimmune cytopenias in IEI have often a more severe, chronic, and relapsing course. Treatment refractoriness also characterizes autoimmune cytopenia with a monogenic cause, such as IEI. The mechanisms underlying autoimmune cytopenias in IEI include cellular or humoral autoimmunity, immune dysregulation in cases of hemophagocytosis or lymphoproliferation with or without splenic sequestration, bone marrow failure, myelodysplasia, or secondary myelosuppression. Genetic characterization of autoimmune cytopenias is of fundamental importance as an early diagnosis improves the outcome and allows the setting up of a targeted therapy, such as CTLA-4 IgG fusion protein (Abatacept), small molecule inhibitors (JAK-inhibitors), or gene therapy. Currently, gene therapy represents one of the most attractive targeted therapeutic approaches to treat selected inborn errors of immunity. Even in the absence of specific targeted therapies, however, whole exome genetic testing (WES) for children with chronic multilineage cytopenias should be considered as an early diagnostic tool for disease diagnosis and genetic counseling.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Cortesi, Soresina, Dotta, Gorio, Cattalini, Lougaris, Porta and Badolato.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cortesi</LastName>
            <ForeName>Manuela</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Paediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, ASST- Spedali Civili of Brescia, University of Brescia, Brescia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soresina</LastName>
            <ForeName>Annarosa</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Paediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, ASST- Spedali Civili of Brescia, University of Brescia, Brescia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dotta</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Paediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, ASST- Spedali Civili of Brescia, University of Brescia, Brescia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gorio</LastName>
            <ForeName>Chiara</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Paediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, ASST- Spedali Civili of Brescia, University of Brescia, Brescia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cattalini</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Paediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, ASST- Spedali Civili of Brescia, University of Brescia, Brescia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lougaris</LastName>
            <ForeName>Vassilios</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>Paediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, ASST- Spedali Civili of Brescia, University of Brescia, Brescia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Porta</LastName>
            <ForeName>Fulvio</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Paediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, ASST- Spedali Civili of Brescia, University of Brescia, Brescia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Badolato</LastName>
            <ForeName>Raffaele</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Paediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, ASST- Spedali Civili of Brescia, University of Brescia, Brescia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536380">Evans Syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000744" MajorTopicYN="Y">Anemia, Hemolytic, Autoimmune</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016553" MajorTopicYN="Y">Purpura, Thrombocytopenic, Idiopathic</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013921" MajorTopicYN="Y">Thrombocytopenia</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">autoimmune cytopenias</Keyword>
        <Keyword MajorTopicYN="N">gene therapy</Keyword>
        <Keyword MajorTopicYN="N">genetic disorders</Keyword>
        <Keyword MajorTopicYN="N">inborn errors of immunity (IEI)</Keyword>
        <Keyword MajorTopicYN="N">target therapy</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35464467</ArticleId>
        <ArticleId IdType="pmc">PMC9019165</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2022.846660</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. . Human Inborn Errors of Immunity: 2019 Update on the Classification From the International Union of Immunological Societies Expert Committee. J Clin Immunol (2020) 40(1):24–64. doi: 10.1007/s10875-019-00737-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-019-00737-x</ArticleId>
            <ArticleId IdType="pmc">PMC7082301</ArticleId>
            <ArticleId IdType="pubmed">31953710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. . Correction to: Human Inborn Errors of Immunity: 2019 Update on the Classification From the International Union of Immunological Societies Expert Committee. J Clin Immunol (2020) 40(1):65. doi: 10.1007/s10875-020-00763-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-020-00763-0</ArticleId>
            <ArticleId IdType="pmc">PMC7645445</ArticleId>
            <ArticleId IdType="pubmed">32086639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, et al. . Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency. J Allergy Clin Immunol (2015) 136(5):1186–205
e1–78. doi: 10.1016/j.jaci.2015.04.049
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2015.04.049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thalhammer J, Kindle G, Nieters A, Rusch S, Seppänen MRJ, Fischer A, et al. . Initial Presenting Manifestations in 16,486 Patients With Inborn Errors of Immunity Include Infections and Noninfectious Manifestations. J Allergy Clin Immunol (2021) 148(5):1332–41.e5. doi: 10.1016/j.jaci.2021.04.015
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2021.04.015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Delmonte OM, Villa A, Notarangelo LD. Immune Dysregulation in Patients With RAG Deficiency and Other Forms of Combined Immune Deficiency. Blood (2020) 135(9):610–9. doi: 10.1182/blood.2019000923
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2019000923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hadjadj J, Aladjidi N, Fernandes H, Leverger G, Magérus-Chatinet A, Mazerolles F, et al. . Pediatric Evans Syndrome is Associated With a High Frequency of Potentially Damaging Variants in Immune Genes. Blood (2019) 134(1):9–21. doi: 10.1182/blood-2018-11-887141
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-11-887141</ArticleId>
            <ArticleId IdType="pubmed">30940614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zama D, Conti F, Moratti M, Cantarini ME, Facchini E, Rivalta B, et al. . Immune Cytopenias as a Continuum in Inborn Errors of Immunity: An in-Depth Clinical and Immunological Exploration. Immun Inflamm Dis (2021) 9(2):583–94. doi: 10.1002/iid3.420
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/iid3.420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Seidel MG. Autoimmune and Other Cytopenias in Primary Immunodeficiencies: Pathomechanisms, Novel Differential Diagnoses, and Treatment. Blood (2014) 124(15):2337–44. doi: 10.1182/blood-2014-06-583260
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-06-583260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gambineri E, Torgerson TR. Genetic Disorders With Immune Dysregulation. Cell Mol Life Sci CMLS (2012) 69(1):49–58. doi: 10.1007/s00018-011-0838-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-011-0838-8</ArticleId>
            <ArticleId IdType="pubmed">21984607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mauracher AA, Gujer E, Bachmann LM, Güsewell S, Pachlopnik Schmid J. Patterns of Immune Dysregulation in Primary Immunodeficiencies: A Systematic Review. J Allergy Clin Immunol In Pract (2021) 9(2):792–802.e10. doi: 10.1016/j.jaip.2020.10.057
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaip.2020.10.057</ArticleId>
            <ArticleId IdType="pubmed">33186766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Seidel MG. Treatment of Immune-Mediated Cytopenias in Patients With Primary Immunodeficiencies and Immune Regulatory Disorders (PIRDs). Hematol Am Soc Hematol Educ Program (2020) 2020(1):673–9. doi: 10.1182/hematology.2020000153
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/hematology.2020000153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim TO, Despotovic JM. Primary and Secondary Immune Cytopenias: Evaluation and Treatment Approach in Children. Hematol/Oncol Clinics North America (2019) 33(3):489–506. doi: 10.1016/j.hoc.2019.01.005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.hoc.2019.01.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zanella A, Barcellini W. Treatment of Autoimmune Hemolytic Anemias. Haematologica (2014) 99(10):1547–54. doi: 10.3324/haematol.2014.114561
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2014.114561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Teachey DT, Lambert MP. Diagnosis and Management of Autoimmune Cytopenias in Childhood. Pediatr Clinics North Am (2013) 60(6):1489–511. doi: 10.1016/j.pcl.2013.08.009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pcl.2013.08.009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gu H, Chen Z, Shi X, Cui H, Qin X, Hu H, et al. . Increased Proportion of Th17/Treg Cells at the New Diagnosed Stage of Chronic Immune Thrombocytopenia in Pediatrics: The Pilot Study From a Multi-Center. Eur J Pediatr (2021) 180(11):3411–7. doi: 10.1007/s00431-021-04121-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00431-021-04121-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rotz SJ, Ware RE, Kumar A. Diagnosis and Management of Chronic and Refractory Immune Cytopenias in Children, Adolescents, and Young Adults. Pediatr Blood Cancer (2018) 65(10):e27260. doi: 10.1002/pbc.27260
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.27260</ArticleId>
            <ArticleId IdType="pubmed">29856527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Afzal W, Owlia MB, Hasni S, Newman KA. Autoimmune Neutropenia Updates: Etiology, Pathology, and Treatment. South Med J (2017) 110(4):300–7. doi: 10.14423/SMJ.0000000000000637
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14423/SMJ.0000000000000637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Callejas Caballero I, Illán Ramos M, Berzosa Sánchez A, Anguita E, Ramos Amador JT. Autoimmune Neutropenia Associated With Influenza Virus Infection in Childhood: A Case Report. BMC Infect Dis (2021) 21(1):830. doi: 10.1186/s12879-021-06506-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12879-021-06506-9</ArticleId>
            <ArticleId IdType="pmc">PMC8371585</ArticleId>
            <ArticleId IdType="pubmed">34407762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med (2021) 385(15):1407–19. doi: 10.1056/NEJMra2033982
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra2033982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, et al. . Diagnosis and Treatment of Autoimmune Hemolytic Anemia in Adults: Recommendations From the First International Consensus Meeting. Blood Rev (2020) 41:100648. doi: 10.1016/j.blre.2019.100648
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.blre.2019.100648</ArticleId>
            <ArticleId IdType="pubmed">31839434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. The Diagnosis and Management of Primary Autoimmune Haemolytic Anaemia. Br J Of Haematol (2017) 176(3):395–411. doi: 10.1111/bjh.14478
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.14478</ArticleId>
            <ArticleId IdType="pubmed">28005293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brodsky RA. Warm Autoimmune Hemolytic Anemia. N Engl J Med (2019) 381(7):647–54. doi: 10.1056/NEJMcp1900554
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMcp1900554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fadlallah J, Michel M, Crickx E, Limal N, Costedoat N, Malphettes M, et al. . Bortezomib and Dexamethasone, an Original Approach for Treating Multi-Refractory Warm Autoimmune Haemolytic Anaemia. Br J Of Haematol (2019) 187(1):124–8. doi: 10.1111/bjh.16009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.16009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Berentsen S. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Front Immunol (2020) 11:590. doi: 10.3389/fimmu.2020.00590
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00590</ArticleId>
            <ArticleId IdType="pmc">PMC7154122</ArticleId>
            <ArticleId IdType="pubmed">32318071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Witkowski M, Witkowska M, Robak T. Autoimmune Thrombocytopenia: Current Treatment Options in Adults With a Focus on Novel Drugs. Eur J Of Haematol (2019) 103(6):531–41. doi: 10.1111/ejh.13319
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejh.13319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Miano M. How I Manage Evans Syndrome and AIHA Cases in Children. Br J Of Haematol (2016) 172(4):524–34. doi: 10.1111/bjh.13866
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.13866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sulpizio ED, Raghunathan V, Shatzel JJ, Zilberman-Rudenko J, Worrest T, Sheppard BC, et al. . Long-Term Remission Rates After Splenectomy in Adults With Evans Syndrome Compared to Immune Thrombocytopenia: A Single-Center Retrospective Study. Eur J Haematol (2020) 104(1):55–8. doi: 10.1111/ejh.13336
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejh.13336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barcellini W, Fattizzo B. The Changing Landscape of Autoimmune Hemolytic Anemia. Front Immunol (2020) 11:946. doi: 10.3389/fimmu.2020.00946
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00946</ArticleId>
            <ArticleId IdType="pmc">PMC7325906</ArticleId>
            <ArticleId IdType="pubmed">32655543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of Mice and Men: An Open-Label Pilot Study for Treatment of Immune Thrombocytopenic Purpura by an Inhibitor of Syk. Blood (2009) 113(14):3154–60. doi: 10.1182/blood-2008-07-166439
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2008-07-166439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barcellini W, Zaninoni A, Giannotta JA, Fattizzo B. New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1. J Clin Med (2020) 9(12). doi: 10.3390/jcm9123859
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm9123859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lledo-Garcia R, Dixon K, Shock A, Oliver R. Pharmacokinetic-Pharmacodynamic Modelling of the Anti-FcRn Monoclonal Antibody Rozanolixizumab: Translation From Preclinical Stages to the Clinic. CPT: Pharmacometrics Syst Pharmacol (2022) 11(1):116–28. doi: 10.1002/psp4.12739
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/psp4.12739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Robak T, Kaźmierczak M, Jarque I, Musteata V, Treliński J, Cooper N, et al. . Phase 2 Multiple-Dose Study of an FcRn Inhibitor, Rozanolixizumab, in Patients With Primary Immune Thrombocytopenia. Blood Adv (2020) 4(17):4136–46. doi: 10.1182/bloodadvances.2020002003
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2020002003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Blair HA, Duggan ST. Belimumab: A Review in Systemic Lupus Erythematosus. Drugs (2018) 78(3):355–66. doi: 10.1007/s40265-018-0872-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40265-018-0872-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao YB, Li JM, Wei BW, Xu ZZ. BAFF Level Increased in Patients With Autoimmune Hemolytic Anemia. Int J Clin Exp Med (2015) 8(3):3876–82.</Citation>
        </Reference>
        <Reference>
          <Citation>
Westermann-Clark E, Meehan CA, Meyer AK, Dasso JF, Amre D, Ellison M, et al. . Primary Immunodeficiency in Children With Autoimmune Cytopenias: Retrospective 154-Patient Cohort. Front Immunol (2021) 12:649182. doi: 10.3389/fimmu.2021.649182
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.649182</ArticleId>
            <ArticleId IdType="pmc">PMC8100326</ArticleId>
            <ArticleId IdType="pubmed">33968040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grimes AB, Kim TO, Kirk SE, Flanagan J, Lambert MP, Grace RF, et al. . Refractory Autoimmune Cytopenias in Pediatric Evans Syndrome With Underlying Systemic Immune Dysregulation. Eur J Haematol (2021) 106(6):783–7. doi: 10.1111/ejh.13600
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ejh.13600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grimbacher B, Warnatz K, Yong PFK, Korganow AS, Peter HH. The Crossroads of Autoimmunity and Immunodeficiency: Lessons From Polygenic Traits and Monogenic Defects. J Allergy Clin Immunol (2016) 137(1):3–17. doi: 10.1016/j.jaci.2015.11.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2015.11.004</ArticleId>
            <ArticleId IdType="pubmed">26768758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Al Ghaithi I, Wright NA, Breakey VR, Cox K, Warias A, Wong T, et al. . Combined Autoimmune Cytopenias Presenting in Childhood. Pediatr Blood Cancer (2016) 63(2):292–8. doi: 10.1002/pbc.25769
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.25769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gámez-Díaz L, Grimbacher B. Immune Checkpoint Deficiencies and Autoimmune Lymphoproliferative Syndromes. Biomed J (2021) 44(4):400–11. doi: 10.1016/j.bj.2021.04.005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bj.2021.04.005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bosticardo M, Ohigashi I, Cowan JE, Alves NL. Editorial: Thymic Epithelial Cells: New Insights Into the Essential Driving Force of T-Cell Differentiation. Front Immunol (2021) 12:744623. doi: 10.3389/fimmu.2021.744623
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.744623</ArticleId>
            <ArticleId IdType="pmc">PMC8414565</ArticleId>
            <ArticleId IdType="pubmed">34484248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Martino L, Capalbo D, Improda N, Lorello P, Ungaro C, Di Mase R, et al. . Novel Findings Into AIRE Genetics and Functioning: Clinical Implications. Front Pediatr (2016) 4:86. doi: 10.3389/fped.2016.00086
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fped.2016.00086</ArticleId>
            <ArticleId IdType="pmc">PMC4992815</ArticleId>
            <ArticleId IdType="pubmed">27597936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Husebye ES, Anderson MS, Kämpe O. Autoimmune Polyendocrine Syndromes. N Engl J Med (2018) 378(12):1132–41. doi: 10.1056/NEJMra1713301
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1713301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Su MA, Anderson MS. Aire: An Update. Curr Opin Immunol (2004) 16(6):746–52. doi: 10.1016/j.coi.2004.09.009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coi.2004.09.009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cavadini P, Vermi W, Facchetti F, Fontana S, Nagafuchi S, Mazzolari E, et al. . AIRE Deficiency in Thymus of 2 Patients With Omenn Syndrome. J Clin Invest (2005) 115(3):728–32. doi: 10.1172/JCI200523087
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI200523087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Somech R, Simon AJ, Lev A, Dalal I, Spirer Z, Goldstein I, et al. . Reduced Central Tolerance in Omenn Syndrome Leads to Immature Self-Reactive Oligoclonal T Cells. J Allergy Clin Immunol (2009) 124(4):793–800. doi: 10.1016/j.jaci.2009.06.048
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.06.048</ArticleId>
            <ArticleId IdType="pubmed">19767069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Capalbo D, Giardino G, Martino LD, Palamaro L, Romano R, Gallo V, et al. . Genetic Basis of Altered Central Tolerance and Autoimmune Diseases: A Lesson From AIRE Mutations. Int Rev Immunol (2012) 31(5):344–62. doi: 10.3109/08830185.2012.697230
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08830185.2012.697230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saifi M, Wysocki CA. Autoimmune Disease in Primary Immunodeficiency: At the Crossroads of Anti-Infective Immunity and Self-Tolerance. Immunol Allergy Clinics North Am (2015) 35(4):731–52. doi: 10.1016/j.iac.2015.07.007
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.iac.2015.07.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grover P, Goel PN, Greene MI. Regulatory T Cells: Regulation of Identity and Function. Front Immunol (2021) 12:750542. doi: 10.3389/fimmu.2021.750542
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.750542</ArticleId>
            <ArticleId IdType="pmc">PMC8524049</ArticleId>
            <ArticleId IdType="pubmed">34675933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Teft WA, Madrenas J. The Immunological Synapse as a Novel Therapeutic Target. Curr Opin Investigational Drugs (London Engl 2000) (2006) 7(11):1008–13.</Citation>
        </Reference>
        <Reference>
          <Citation>
Massaad MJ, Ramesh N, Geha RS. Wiskott-Aldrich Syndrome: A Comprehensive Review. Ann New York Acad Sci (2013) 1285:26–43. doi: 10.1111/nyas.12049
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nyas.12049</ArticleId>
            <ArticleId IdType="pubmed">23527602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gámez-Díaz L, Seidel MG. Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights Into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies. Front Pediatr (2021) 9:662645. doi: 10.3389/fped.2021.662645
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fped.2021.662645</ArticleId>
            <ArticleId IdType="pmc">PMC8113415</ArticleId>
            <ArticleId IdType="pubmed">33996698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lorenzini T, Dotta L, Giacomelli M, Vairo D, Badolato R. STAT Mutations as Program Switchers: Turning Primary Immunodeficiencies Into Autoimmune Diseases. J Leukocyte Biol (2017) 101(1):29–38. doi: 10.1189/jlb.5RI0516-237RR
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.5RI0516-237RR</ArticleId>
            <ArticleId IdType="pubmed">27803128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Okada S, Asano T, Moriya K, Boisson-Dupuis S, Kobayashi M, Casanova JL, et al. . Human STAT1 Gain-Of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy. J Clin Immunol (2020) 40(8):1065–81. doi: 10.1007/s10875-020-00847-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-020-00847-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cepika AM, Sato Y, Liu JM, Uyeda MJ, Bacchetta R, Roncarolo MG. Tregopathies: Monogenic Diseases Resulting in Regulatory T-Cell Deficiency. J Allergy Clin Immunol (2018) 142(6):1679–95. doi: 10.1016/j.jaci.2018.10.026
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2018.10.026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nunes-Santos CJ, Uzel G, Rosenzweig SD. PI3K Pathway Defects Leading to Immunodeficiency and Immune Dysregulation. J Allergy Clin Immunol (2019) 143(5):1676–87. doi: 10.1016/j.jaci.2019.03.017
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2019.03.017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vogel TP, Milner JD, Cooper MA. The Ying and Yang of STAT3 in Human Disease. J Clin Immunol (2015) 35(7):615–23. doi: 10.1007/s10875-015-0187-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-015-0187-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, et al. . Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. J Clin Immunol (2020) 40(1):66–81. doi: 10.1007/s10875-020-00758-x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10875-020-00758-x</ArticleId>
            <ArticleId IdType="pmc">PMC7082388</ArticleId>
            <ArticleId IdType="pubmed">32048120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. . Common Variable Immunodeficiency Disorders: Division Into Distinct Clinical Phenotypes. Blood (2008) 112(2):277–86. doi: 10.1182/blood-2007-11-124545
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2007-11-124545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Costagliola G, Cappelli S, Consolini R. Autoimmunity in Primary Immunodeficiency Disorders: An Updated Review on Pathogenic and Clinical Implications. J Clin Med (2021) 10(20):4729. doi: 10.3390/jcm10204729
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jcm10204729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vlkova M, Ticha O, Nechvatalova J, Kalina T, Litzman J, Mauri C, et al. . Regulatory B Cells in CVID Patients Fail to Suppress Multifunctional IFN-γ+ TNF-α+ CD4+ T Cells Differentiation. Clin Immunol (Orlando Fla) (2015) 160(2):292–300. doi: 10.1016/j.clim.2015.06.013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2015.06.013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Warnatz K, Voll RE. Pathogenesis of Autoimmunity in Common Variable Immunodeficiency. Front Immunol (2012) 3:210. doi: 10.3389/fimmu.2012.00210
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2012.00210</ArticleId>
            <ArticleId IdType="pmc">PMC3399211</ArticleId>
            <ArticleId IdType="pubmed">22826712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
de Valles-Ibáñez G, Esteve-Solé A, Piquer M, González-Navarro EA, Hernandez-Rodriguez J, Laayouni H, et al. . Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond. Front Immunol (2018) 9:636. doi: 10.3389/fimmu.2018.00636
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.00636</ArticleId>
            <ArticleId IdType="pmc">PMC5960686</ArticleId>
            <ArticleId IdType="pubmed">29867916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Davies EG, Thrasher AJ. Update on the Hyper Immunoglobulin M Syndromes. Br J Haematol (2010) 149(2):167–80. doi: 10.1111/j.1365-2141.2010.08077.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2141.2010.08077.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jamee M, Moniri S, Zaki-Dizaji M, Olbrich P, Yazdani R, Jadidi-Niaragh F, et al. . Clinical, Immunological, and Genetic Features in Patients With Activated Pi3kδ Syndrome (APDS): A Systematic Review. Clin Rev Allergy Immunol (2020) 59(3):323–33. doi: 10.1007/s12016-019-08738-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12016-019-08738-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell (2017) 169(2):361–71. doi: 10.1016/j.cell.2017.03.035
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.03.035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Delmonte OM, Notarangelo LD. Targeted Therapy With Biologicals and Small Molecules in Primary Immunodeficiencies. Med principles Pract Int J Kuwait Univ Health Sci Centre (2020) 29(2):101–12. doi: 10.1159/000503997
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000503997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bevacqua M, Baldo F, Pastore S, Valencic E, Tommasini A, Maestro A, et al. . Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the Literature. Paediatric Drugs (2019) 21(3):185–93. doi: 10.1007/s40272-019-00337-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40272-019-00337-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lanz AL, Riester M, Peters P, Schwerd T, Lurz E, Hajji MS, et al. . Abatacept for Treatment-Refractory Pediatric CTLA4-Haploinsufficiency. Clin Immunol (Orlando Fla) (2021) 229:108779. doi: 10.1016/j.clim.2021.108779
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clim.2021.108779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dhunputh C, Ducassou S, Fernandes H, Picard C, Rieux-Laucat F, Viallard JF, et al. . Abatacept is Useful in Auto-Immune Cytopenia With Immunopathologic Manifestations Caused by CTLA-4 Defects. Blood (2021) 139(2):151–305. doi: 10.1182/blood.2021013496
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2021013496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kiykim A, Ogulur I, Dursun E, Charbonnier LM, Nain E, Cekic S, et al. . Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J Allergy Clin Immunol In Pract (2019) 7(8):2790–800.e15. doi: 10.1016/j.jaip.2019.06.011
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaip.2019.06.011</ArticleId>
            <ArticleId IdType="pmc">PMC6842687</ArticleId>
            <ArticleId IdType="pubmed">31238161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tesch VK, Abolhassani H, Shadur B, Zobel J, Mareika Y, Sharapova S, et al. . Long-Term Outcome of LRBA Deficiency in 76 Patients After Various Treatment Modalities as Evaluated by the Immune Deficiency and Dysregulation Activity (IDDA) Score. J Allergy Clin Immunol (2020) 145(5):1452–63. doi: 10.1016/j.jaci.2019.12.896
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2019.12.896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, et al. . Jakinibs for the Treatment of Immune Dysregulation in Patients With Gain-of-Function Signal Transducer and Activator of Transcription 1 (STAT1) or STAT3 Mutations. J Allergy Clin Immunol (2018) 142(5):1665–9. doi: 10.1016/j.jaci.2018.07.020
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2018.07.020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Elkaim E, Neven B, Bruneau J, Mitsui-Sekinaka K, Stanislas A, Heurtier L, et al. . Clinical and Immunologic Phenotype Associated With Activated Phosphoinositide 3-Kinase δ Syndrome 2: A Cohort Study. J Allergy Clin Immunol (2016) 138(1):210–8.e9. doi: 10.1016/j.jaci.2016.03.022
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2016.03.022</ArticleId>
            <ArticleId IdType="pubmed">27221134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maccari ME, Abolhassani H, Aghamohammadi A, Aiuti A, Aleinikova O, Bangs C, et al. . Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry. Front Immunol (2018) 9:543. doi: 10.3389/fimmu.2018.00543
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2018.00543</ArticleId>
            <ArticleId IdType="pmc">PMC5863269</ArticleId>
            <ArticleId IdType="pubmed">29599784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Okano T, Imai K, Tsujita Y, Mitsuiki N, Yoshida K, Kamae C, et al. . Hematopoietic Stem Cell Transplantation for Progressive Combined Immunodeficiency and Lymphoproliferation in Patients With Activated Phosphatidylinositol-3-OH Kinase δ Syndrome Type 1. J Allergy Clin Immunol (2019) 143(1):266–75. doi: 10.1016/j.jaci.2018.04.032
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2018.04.032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nademi Z, Slatter MA, Dvorak CC, Neven B, Fischer A, Suarez F, et al. . Hematopoietic Stem Cell Transplant in Patients With Activated PI3K Delta Syndrome. J Allergy Clin Immunol (2017) 139(3):1046–9. doi: 10.1016/j.jaci.2016.09.040
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2016.09.040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rao VK, Webster S, Dalm V, Šedivá A, van Hagen PM, Holland S, et al. . Effective "Activated PI3Kδ Syndrome"-Targeted Therapy With the PI3Kδ Inhibitor Leniolisib. Blood (2017) 130(21):2307–16. doi: 10.1182/blood-2017-08-801191
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2017-08-801191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bloomfield M, Klocperk A, Zachova R, Milota T, Kanderova V, Sediva A. Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence. Front Pediatr (2021) 9:697706. doi: 10.3389/fped.2021.697706
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fped.2021.697706</ArticleId>
            <ArticleId IdType="pmc">PMC8326455</ArticleId>
            <ArticleId IdType="pubmed">34350147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kohn LA, Kohn DB. Gene Therapies for Primary Immune Deficiencies. Front Immunol (2021) 12:648951. doi: 10.3389/fimmu.2021.648951
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2021.648951</ArticleId>
            <ArticleId IdType="pmc">PMC7946985</ArticleId>
            <ArticleId IdType="pubmed">33717203</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
